Quantcast

Latest Artificial pancreas Stories

2010-11-12 06:00:00

DANBURY, Conn., Nov. 12, 2010 /PRNewswire/ -- Scientists from Biodel Inc. (Nasdaq: BIOD) reported new findings from the company's Linjeta(TM), insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD. Dr. Frank Flacke presented results of a Phase 1 single-center, double-blind, randomized crossover trial in 13 subjects with type 1 diabetes who received a...

2010-11-11 13:43:16

Experts present at FDA-NIH workshop Diabetes experts at a meeting convened by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) took the next step in advancing efforts toward the development of an artificial pancreas: putting forth clinical recommendations to ensure the safe and effective testing of artificial pancreas technology in real-life situations. We are pleased at today's meeting there was a strong consensus among leading clinicians, researchers...

2010-11-08 05:00:00

DANBURY, Conn., Nov. 8, 2010 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following abstracts describing recent findings from the company's product development programs have been accepted for poster presentation at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD, November 11 and 12, 2010: "Characterization of Pharmacokinetics and Toleration of Three Variant Formulations of Linjeta"; presented by Dr. Frank Flacke, November 12 "A Stabilized Liquid...

2010-11-05 15:10:00

Renewal of U.S. Government Special Diabetes Program Will Ensure Progress toward Better Treatments and a Cure for Type 1 Diabetes NEW YORK, Nov. 5, 2010 /PRNewswire-USNewswire/ -- Thanks to significant research advances in recent years, people living with type 1 diabetes have received better treatments and therapies. Scientists have made headway in uncovering the possible cause of type 1 diabetes, and in their efforts to find ways to prevent, treat, or reverse the autoimmune disease and...

8237c2395201e0d8063d204c97e0f22d1
2010-10-28 14:19:46

Anne M Stark, Lawrence Livermore National Laboratory Beta cells, which make insulin in the human body, do not replicate after the age of 30, indicating that clinicians may be closer to better treating diabetes. Type 1 diabetes is caused by a loss of beta cells by auto-immunity while type 2 is due to a relative insufficiency of beta cells. Whether beta cells replicate after birth has remained an open issue, and is critically important for designing therapies for diabetes. By using radioactive...

2010-09-23 08:23:00

DANBURY, Conn., Sept. 23 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported recent findings from the company's diabetes drug research program during a poster session on short-acting insulins at the 46th annual meeting of the European Association for the Study of Diabetes in Stockholm. In the first poster presentation, "Biocompatibility of the ultra-rapid insulin VIAject® (Linjeta(TM)) with continuous insulin infusion sets," Dr. Frank Flacke of Biodel reported that...

2010-07-12 06:00:00

DANBURY, Conn., July 12 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today the award of two research grants by the Juvenile Diabetes Research Foundation (www.jdrf.org) to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use of VIAject® (ultra-rapid-acting injectable human insulin) in the treatment of diabetes. The first grant will support clinical testing under the direction of Bruce Buckingham, M.D., professor of...

2010-06-30 12:43:07

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published online June 29 in the New England Journal of Medicine. The paper is entitled, Effectiveness of Sensor-Augmented Insulin-Pump therapy in Type 1 Diabetes. "Combining the best technologies for insulin delivery and blood sugar monitoring really pays off for...

6872b1e4fb59f967901e4fe5f7c9a4371
2010-06-29 10:42:26

No immune suppression drugs needed In a step toward curing diabetes in humans, scientists at Washington University School of Medicine in St. Louis have alleviated the disease in rats using transplants from both embryonic and adult pigs. The rats adopted the pig transplants as their own and produced enough insulin to control their blood sugar "“ all without the need for anti-rejection drugs. The researchers report their findings online in the American Journal of Pathology. Using a...

2010-06-26 09:00:00

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular (CV) events associated with SYMLIN® (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related